Traduction de «directorates-general and other departments and services » (Néerlandais → Français) :

The implementation of the new organisation chart as envisaged for the start of 2009 requires the P&O Service to develop a definition of its future role in terms of the expectations from the 3 Directorates-General and other departments and services, to implement the 1 % reduction imposed for personnel expenditure and to further develop the strategic decision to convert the FAMHP into a “learning organisation”.
The implementation of the new organisation chart as envisaged for the start of 2009 requires the P&O Service to develop a definition of its future role in terms of the expectations from the 3 Directorates-General and other departments and services, to implement the 1 % reduction imposed for personnel expenditure and to further develop the strategic decision to convert the FAMHP into a “learning organisation”.

since March 2008. This database is an important tool used by the FAMHP departments/services in the context of their activities as well as by the BUM Department itself in order to answer the numerous questions posed by healthcare professionals, patients/consumers, relevant industry or other national or foreign authorities.
since March 2008. This database is an important tool used by the FAMHP departments/services in the context of their activities as well as by the BUM Department itself in order to answer the numerous questions posed by healthcare professionals, patients/consumers, relevant industry or other national or foreign authorities.

The FAMHP was established by law on 20 July 2006 and as from 1 January 2007 completely took over the role and fields of competency of the Directorate-General for Medicinal Products (DG Medicinal Products) that was a part of the Federal Public Service (FPS) Public Health, Food Chain Security and Environment.
The FAMHP was established by law on 20 July 2006 and as from 1 January 2007 completely took over the role and fields of competency of the Directorate-General for Medicinal Products (DG Medicinal Products) that was a part of the Federal Public Service (FPS) Public Health, Food Chain Security and Environment.

The FAMHP has completely taken over the role and fields of competency of the Directorate-General for Medicinal Products (DG Medicinal Products) of the Federal Public Service (FPS) Public Health.
The FAMHP has completely taken over the role and fields of competency of the Directorate-General for Medicinal Products (DG Medicinal Products) of the Federal Public Service (FPS) Public Health.

three pillars (PRE, POST and INSPECTION) ●● Integrating the spearheads across the organisation Transversally integrating and coordinating the operational departments and other services
three pillars (PRE, POST and INSPECTION) ●● Integrating the spearheads across the organisation Transversally integrating and coordinating the operational departments and other services

Moreover, NPC entered into a Corporate Integrity Agreement (CIA) with the Office of the Inspector General of the US Department of Health and Human Services.
En outre, NPC a conclu un «corporate integrity agreement» (CIA) avec le bureau de l’inspecteur général du Département de la Santé et des Services sociaux des Etats-Unis (U.S. Department of Health and Human Services).

Acknowledgements: Voor haar waardevolle bijdrage in het gedeelte over meta-analyse: Cécile Dubois (KCE) Voor hun bijdrage bij het scoren van de indicatoren: Raf Brouns en Matthieu Rutgers (Belgian Stroke Council) Voor het valideren van de informatie over hun land: Zweden: Kiell Asplund (Chair, Risks Stroke Umeal), Bo Norrving (Professor, Lund University-Steering committee member Riks stroke) Nederland: Martien Limburg (Neuroloog, Flevoziekenhuis, Almere, Stichting Kennisnetwerk); Schotland: Martin Dennis (Division of Clinical Neurosciences – Western General Hospital University of Edinburgh), Peter Langhorne (Professor of Stroke Care, Cardiovascular and Medical Sciences Division – University of Glasgow) Verenigd Koninkrijk: Patrick Gompertz (Barts and the London Brain Attack Center, London), Gill Gluckie (Clinical lead, stroke, Guy’s and St. Thomas’ hospital, clinical lead, S/East London stroke network) Frankrijk: France Woimant (Service de neurologie, hôpital Lariboisière, Paris – “Agence Régionale de Santé – Ile-de-France”), Didier Leys (Département de neurologie, Hôpital universitaire de Lille) Duitsland: Peter Heuschmann (Neurologische klinik und poliklinik, Universitätsklinikum Würzburg) German Stroke Register Study Group), E. Bernd Ringelstein (Neurologische klinik und poliklinik, Universitätsklinikum Münster)
Remerciements : Pour son aide précieuse relative à la méta-analyse : Cécile Dubois (KCE) Pour leur contribution au scoring des indicateurs : Raf Brouns et Matthieu Rutgers (Belgian Stroke Council) Pour la validation de la description de leur pays : Suède : Kiell Asplund (Chair, Risks Stroke Umea), Bo Norrving (Professor, Lund University-Steering committee member Riks stroke) Pays-Bas : Martien Limburg (Neuroloog, Flevoziekenhuis, Almere, Stichting Kennisnetwerk) Ecosse : Martin Dennis (Division of Clinical Neurosciences – Western General Hospital University of Edinburgh), Peter Langhorne (Professor of Stroke Care, Cardiovascular and Medical Sciences Division – University of Glasgow) Grande-Bretagne : Patrick Gompertz (Barts and the London Brain Attack Center, London), Gill Gluckie (Clinical lead, stroke, Guy’s and St. Thomas’ hospital, clinical lead, S/East London stroke network) France : France Woimant (Service de neurologie, hôpital Lariboisière, Paris – “Agence Régionale de Santé – Ilede-France”), Didier Leys (Département de neurologie, Hôpital universitaire de Lille) Allemagne : Peter Heuschmann (Neurologische klinik und poliklinik, Universitätsklinikum Würzburg) German Stroke Register Study Group), E. Bernd Ringelstein (Neurologische klinik und poliklinik, Universitätsklinikum Münster)

A report from the Surgeon General. [http ...]
A report from the Surgeon General. [http ...]

Guy Coertjens, Business Unit Manager BIS Industrial Services Danny Smet, Senior Ingenieur Persoonlijke Veiligheid en Arbeidshygiëne Fina Antwerp Olefins Christian Dierick, adviseur Agoria sector mechatronica Benoit Pinet, General Management Collaborator FIB Belgium Philip Knipscheer, directeur Gouda Vuurvast Belgium Marc Vogels, Civil Works BASF Antwerpen Werner Van der Steen, Managing Director Keramab Serge Kwasniewski, adviseur gezondheid essenscia Tom Van Weyenberg, Bedrijfsarts BASF Geert De Prez, adviseur veiligheid en gezondheid Agoria
Guy Coertjens, Business Unit Manager BIS Industrial Services Danny Smet, ingénieur en chef, Sécurité des personnes et hygiène au travail, Fina Antwerp Olefins Christian Dierick, conseiller Agoria, secteur mécatronique Benoit Pinet, General Management Collaborator FIB Belgium Philip Knipscheer, directeur de Gouda Vuurvast Belgium Marc Vogels, Civil Works BASF Anvers Werner Van der Steen, Managing Director Keramab Serge Kwasniewski, conseiller Santé, Essenscia Tom Van Weyenberg, médecin du travail BASF Geert De Prez, conseiller Sécurité et santé Agoria

Any settlement may include NPC entering into a Corporate Integrity Agreement with the Office of Inspector General of the U.S. Department of Health and Human Services.
Tout règlement de ce litige peut impliquer que NPC conclue un « corporate integrity agreement » avec l’Inspecteur général du Département de la Santé et des Services sociaux des Etats-Unis (U.S. Department of Health and Human Services).